Nicotine self-administration and locomotor activity are not modified by the 5-HT3 antagonists ICS 205–930 and MDL 72222

This publication has 22 references indexed in Scilit:

• Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area
  Brain Research, 1994
• Behavioural studies on WAY100289, a novel 5-HT3 receptor antagonist, in two animal models of anxiety
  European Journal of Pharmacology, 1992
• The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
  Psychopharmacology, 1992
• Blockade of the discriminative stimulus effects of ethanol with 5-HT3 receptor antagonists
  Psychopharmacology, 1991
• Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question
  Pain, 1991
• Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens
  Brain Research, 1991
• Chronic BRL 43694, a selective 5-HT3 receptor antagonist, fails to alter the number of spontaneously active midbrain dopamine neurons
  European Journal of Pharmacology, 1990
• 5HT3 receptor antagonists block morphine- and nicotine-but not amphetamine-induced reward
  Psychopharmacology, 1989
• Nicotine maintains robust self-administration in rats on a limited-access schedule
  Psychopharmacology, 1989
• Effects of the 5‐HT₃ receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain
  British Journal of Pharmacology, 1987